Posterior reversible encephalopathy syndrome associated with deoxycoformycin and alemtuzumab

J R Coll Physicians Edinb. 2011 Sep;41(3):215-7. doi: 10.4997/JRCPE.2011.306.

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a combined clinical and radiological syndrome characterised by headaches, encephalopathy, seizures and visual loss. We present the case of a 55-year-old male who developed this condition following treatment with deoxycoformycin and alemtuzumab. We review the literature considering diagnosis, pathophysiology and optimal strategies for treatment of this condition.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Neoplasm / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Humans
  • Male
  • Pentostatin / adverse effects*
  • Posterior Leukoencephalopathy Syndrome / chemically induced*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Pentostatin
  • Alemtuzumab